Hub : Traits :

Headache pain in last month

485 significantly associated models · 67 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	149672809	151227371	6	1	1.4e-11	6.9e-11	5.1e-01	99	ECM1
2	1	155739430	157168420	1	1	2.7e-10	4.5e-16	3.9e-08	54	MEF2D
3	1	242590540	244359621	3	1	2.8e-09	1.8e-08	1.0e-01	92	CEP170
4	3	157594704	159140638	3	1	6.9e-08	6.9e-08	1.0e+00	100	RARRES1
5	4	87165758	88754060	1	1	1.7e-07	2.3e-08	1.9e-02	82	AFF1
6	6	12020241	13990267	2	1	2.4e-15	7.2e-16	7.8e-04	83	PHACTR1
7	6	25285943	26689223	1	1	8.6e-08	6.9e-10	4.8e-06	45	U91328.21
8	6	95831017	97756290	4	2	2.5e-26	1.8e-31	7.2e-04	92	FHL5 KIAA0776
9	8	8747245	9255927	1	1	6.7e-08	7.7e-08	2.7e-02	83	PPP1R3B
10	9	70961350	72562779	2	1	5.7e-08	2.5e-09	8.9e-03	81	TJP2
11	10	99973800	101244527	1	1	3.1e-08	9.0e-09	1.0e+00	100	HPSE2
12	11	56774260	58178587	1	1	6.5e-08	2.1e-06	9.6e-03	70	MED19
13	12	55677395	58303535	8	2	1.6e-40	1.6e-40	1.0e+00	100	LRP1 RAB5B
14	12	109739011	111873167	9	2	2.4e-10	2.5e-10	1.0e+00	100	ANKRD13A FAM216A
15	12	111910219	113517494	1	1	2.8e-07	5.0e-07	3.5e-01	97	HECTD4
16	16	74578110	76197034	2	1	4.5e-08	3.7e-08	1.4e-01	93	TMEM170A
17	17	42607368	45796313	21	8	2.4e-18	1.7e-16	1.0e+00	100	ACBD4 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Hair/balding pattern: Pattern 4	22.01	6	6	13.3	-0.99	2.5e-05	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Medication: Paracetamol	14.93	12	11	24.4	0.97	3.2e-08	CEP170 CRHR1-IT1 FHL5 KANSL1 KIAA0776 LRP1 LRRC37A MAPT MEF2D PHACTR1 RP11-669E14.6 U91328.21
Medication: Paracetamol	12.69	11	7	15.6	0.97	1.8e-07	CEP170 CRHR1-IT1 FHL5 KANSL1 KIAA0776 LRP1 LRRC37A MAPT PHACTR1 RP11-669E14.6 U91328.21
Sensitivity / hurt feelings	11.98	7	6	13.3	1.00	9.9e-08	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RP11-669E14.6
Medication for pain relief, constipation, heartburn	11.98	12	8	17.8	-0.97	5.2e-08	CEP170 CRHR1-IT1 FHL5 KANSL1 KIAA0776 LRP1 LRRC37A MAPT MEF2D PHACTR1 RP11-669E14.6 U91328.21
Relative age of first facial hair	11.79	6	6	13.3	0.99	9.2e-06	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Hair/balding pattern: Pattern 3	11.57	6	6	13.3	-0.99	1.0e-05	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Blood Red Count	11.38	11	8	17.8	0.81	1.3e-03	ACBD4 AFF1 ARL17B CRHR1-IT1 HECTD4 KANSL1 LRRC37A MAPT MED19 RAB5B RP11-669E14.6
Neuroticism	11.10	8	6	13.3	0.99	1.2e-06	ARL17B CEP170 CRHR1-IT1 KANSL1 LRRC37A MAPT MED19 RP11-669E14.6
Neuroticism (Nagel 2018)	11.07	7	6	13.3	1.00	1.8e-07	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT MED19 RP11-669E14.6
Lung FVC	10.75	11	8	17.8	-0.73	6.9e-03	AFF1 ARL17B CRHR1-IT1 ECM1 KANSL1 LRRC37A MAPT MEF2D RAB5B RARRES1 RP11-669E14.6
Migraine (self-reported)	10.60	7	4	8.9	1.00	5.2e-07	AFF1 ECM1 FHL5 KIAA0776 LRP1 MEF2D PHACTR1
Neuroticism score	10.26	8	7	15.6	0.99	7.2e-08	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT MED19 PPP1R3B RP11-669E14.6
Depressed Affect (Nagel 2018)	9.90	7	7	15.6	1.00	2.8e-07	ARL17B CEP170 CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Medication: Ibuprofen (e.g. Nurofen)	9.90	10	1	2.2	0.98	2.0e-07	CRHR1-IT1 HECTD4 KIAA0776 LRP1 MAPT MEF2D PHACTR1 RP11-669E14.6 TJP2 U91328.21
Forced expiratory volume in 1-second (FEV1)	9.41	9	8	17.8	-0.78	7.3e-03	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RAB5B RP11-669E14.6 TMEM170A U91328.21
Forced expiratory volume in 1-second (FEV1), predicted percentage	8.95	10	8	17.8	-0.58	6.3e-02	ARL17B CRHR1-IT1 ECM1 KANSL1 LRRC37A MAPT RAB5B RP11-669E14.6 TMEM170A U91328.21
Forced expiratory volume in 1-second (FEV1), Best measure	8.74	9	8	17.8	-0.79	7.1e-03	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RAB5B RP11-669E14.6 TMEM170A U91328.21
Ovarian Cancer	8.67	5	5	11.1	-0.99	5.6e-05	CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Mood swings	8.52	6	6	13.3	0.99	3.7e-06	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Forced vital capacity (FVC)	8.10	7	7	15.6	-0.89	3.3e-03	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6 U91328.21
Frequency of tenseness / restlessness in last 2 weeks	8.08	7	6	13.3	0.99	1.3e-06	ACBD4 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Forced vital capacity (FVC), Best measure	7.81	8	7	15.6	-0.86	3.1e-03	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RAB5B RP11-669E14.6 U91328.21
Medication: Ibuprofen	7.81	4	1	2.2	0.93	2.2e-02	CRHR1-IT1 LRP1 MEF2D PHACTR1
Relative age voice broke	7.78	5	5	11.1	0.99	1.3e-04	CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Blood Eosinophil Count	7.75	12	10	22.2	-0.79	1.2e-03	ACBD4 ARL17B CRHR1-IT1 ECM1 HECTD4 KANSL1 LRP1 LRRC37A MAPT MED19 RAB5B RP11-669E14.6
Pain experienced in last month	7.30	9	1	2.2	-0.98	7.4e-07	CEP170 CRHR1-IT1 FHL5 HECTD4 LRP1 MAPT PHACTR1 RAB5B RP11-669E14.6
Fed-up feelings	7.14	7	5	11.1	0.99	4.5e-07	CRHR1-IT1 HECTD4 KANSL1 LRRC37A MAPT PPP1R3B RP11-669E14.6
Mouth/teeth dental problems: Mouth ulcers	6.78	6	5	11.1	1.00	6.5e-08	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Neuroticism (2016)	6.32	5	3	6.7	1.00	2.1e-07	CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Peak expiratory flow (PEF)	5.96	9	7	15.6	-0.62	5.7e-02	ARL17B CRHR1-IT1 ECM1 KANSL1 LRRC37A MAPT RP11-669E14.6 TMEM170A U91328.21
Miserableness	5.63	5	3	6.7	0.99	8.5e-05	CRHR1-IT1 KANSL1 LRRC37A PPP1R3B RP11-669E14.6
Lung FEV1/FVC ratio	5.60	8	4	8.9	-0.40	2.8e-01	CRHR1-IT1 LRP1 MAPT MEF2D PPP1R3B RAB5B RP11-669E14.6 TMEM170A
Nervous feelings	5.59	7	2	4.4	1.00	1.7e-07	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RP11-669E14.6
Worry (Nagel 2018)	5.55	6	5	11.1	1.00	2.1e-07	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Alcohol intake frequency.	5.42	8	4	8.9	0.95	8.0e-05	CRHR1-IT1 KANSL1 LRP1 LRRC37A MAPT MED19 RAB5B RP11-669E14.6
Systolic blood pressure, automated reading	5.40	12	6	13.3	-0.39	1.9e-01	ANKRD13A CRHR1-IT1 FHL5 HECTD4 KANSL1 KIAA0776 MAPT MED19 PHACTR1 PPP1R3B RP11-669E14.6 TMEM170A
Irritability	5.35	7	3	6.7	0.99	8.3e-07	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RP11-669E14.6
Guilty feelings	5.20	6	0	0.0	1.00	2.8e-06	ARL17B CRHR1-IT1 KANSL1 LRRC37A MED19 RP11-669E14.6
Systolic Blood Pressure	5.12	12	10	22.2	-0.32	2.8e-01	ANKRD13A CRHR1-IT1 FHL5 HECTD4 KANSL1 KIAA0776 MAPT MED19 MEF2D PHACTR1 RP11-669E14.6 TMEM170A
Waist Hip Ratio (WHR)	5.06	7	6	13.3	0.99	3.1e-06	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT MEF2D RP11-669E14.6
Handedness (chirality/laterality): Left-handed	5.03	4	1	2.2	-0.99	1.9e-03	ARL17B CRHR1-IT1 LRRC37A RP11-669E14.6
Hair/balding pattern: Pattern 2	4.86	5	0	0.0	0.99	7.7e-05	CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Depression (Nagel 2018)	4.80	4	0	0.0	1.00	1.3e-04	ACBD4 ARL17B CRHR1-IT1 MED19
Frequency of depressed mood in last 2 weeks	4.67	4	0	0.0	0.98	3.2e-03	ARL17B CRHR1-IT1 MED19 PPP1R3B
Average weekly champagne plus white wine intake	4.64	5	1	2.2	-0.99	3.0e-04	CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Loneliness, isolation	4.58	2	0	0.0	0.00	1.0e+00	CRHR1-IT1 LRRC37A
Qualifications: College or University degree	4.55	7	7	15.6	-0.99	1.6e-06	CEP170 CRHR1-IT1 KANSL1 LRRC37A MAPT RAB5B RP11-669E14.6
Worrier / anxious feelings	4.50	7	3	6.7	0.99	3.4e-06	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RP11-669E14.6
Primary Biliary Cirrhosis	4.44	6	0	0.0	-0.60	1.5e-01	CRHR1-IT1 HECTD4 LRP1 LRRC37A MAPT RP11-669E14.6
Hand grip strength (left)	4.40	7	5	11.1	-0.81	1.5e-02	ARL17B CRHR1-IT1 ECM1 KANSL1 LRRC37A MAPT RP11-669E14.6
Worry too long after embarrassment	4.19	5	1	2.2	0.98	8.4e-04	ARL17B CRHR1-IT1 MAPT MED19 RP11-669E14.6
Medication: Levothyroxine sodium	4.17	2	2	4.4	0.00	1.0e+00	HECTD4 RAB5B
Breast Cancer	4.16	5	3	6.7	1.00	5.1e-07	CRHR1-IT1 KANSL1 LRRC37A MAPT RP11-669E14.6
Hypothyroidism/myxoedema (self-reported)	4.15	2	2	4.4	0.00	1.0e+00	HECTD4 RAB5B
Hypothyroidism (self reported)	4.06	3	2	4.4	0.00	1.0e+00	FAM216A HECTD4 RAB5B
Time employed in main current job	4.01	3	0	0.0	0.00	1.0e+00	KANSL1 LRRC37A RP11-669E14.6
Coronary Artery Disease (CAD)	3.99	2	1	2.2	0.00	1.0e+00	HECTD4 PHACTR1
Sitting height	3.97	10	8	17.8	-0.60	4.9e-02	ACBD4 ARL17B CRHR1-IT1 ECM1 KANSL1 LRP1 LRRC37A MAPT PPP1R3B RP11-669E14.6
Hand grip strength (right)	3.88	7	6	13.3	-0.77	2.6e-02	ARL17B CRHR1-IT1 ECM1 KANSL1 LRRC37A MAPT RP11-669E14.6
Diastolic blood pressure, automated reading	3.86	4	4	8.9	-0.21	7.9e-01	CEP170 HECTD4 PPP1R3B U91328.21
Vitamin and mineral supplements	3.81	2	1	2.2	0.00	1.0e+00	LRP1 RP11-669E14.6
Impedance of arm (left)	3.81	8	5	11.1	-0.88	1.5e-03	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RAB5B RP11-669E14.6
Heel T-Score	3.80	11	9	20.0	-0.61	3.6e-02	ACBD4 AFF1 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT MED19 MEF2D RAB5B RP11-669E14.6
Medication: Blood pressure	3.71	5	0	0.0	-0.99	1.2e-04	CRHR1-IT1 HECTD4 KANSL1 MAPT RP11-669E14.6
Ever unenthusiastic/disinterested for a whole week	3.67	2	0	0.0	0.00	1.0e+00	CRHR1-IT1 LRRC37A
Frequency of unenthusiasm / disinterest in last 2 weeks	3.61	2	0	0.0	0.00	1.0e+00	ACBD4 PPP1R3B
Mouth/teeth dental problems	3.47	4	0	0.0	-0.99	1.0e-03	CEP170 CRHR1-IT1 MAPT RP11-669E14.6
Fluid intelligence score	3.46	3	0	0.0	-0.15	8.5e-01	CRHR1-IT1 RAB5B U91328.21
Frequency of tiredness / lethargy in last 2 weeks	3.43	2	1	2.2	0.00	1.0e+00	HECTD4 MED19
Hearing difficulty/problems with background noise	3.42	3	0	0.0	1.00	2.4e-03	CRHR1-IT1 KANSL1 RP11-669E14.6
Number of live births	3.42	1	0	0.0	0.00	1.0e+00	CRHR1-IT1
Verbal and Numeric Reasoning (VNR)	3.41	7	1	2.2	-0.97	4.9e-05	ARL17B CRHR1-IT1 FAM216A MAPT RAB5B RP11-669E14.6 U91328.21
Impedance of arm (right)	3.29	9	6	13.3	-0.87	1.1e-03	AFF1 ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RAB5B RP11-669E14.6
Number of treatments/medications taken	3.25	2	0	0.0	0.00	1.0e+00	LRP1 MEF2D
Impedance of whole body	3.25	8	5	11.1	-0.89	1.3e-03	ARL17B CRHR1-IT1 KANSL1 LRRC37A MAPT PPP1R3B RAB5B RP11-669E14.6
Supplements: Vitamin C	3.24	1	0	0.0	0.00	1.0e+00	RP11-669E14.6
Qualifications: A levels/AS levels or equivalent	3.22	4	0	0.0	-0.99	7.2e-04	CEP170 CRHR1-IT1 RAB5B RP11-669E14.6
Leg pain on walking	3.17	1	0	0.0	0.00	1.0e+00	MAPT
Asthma (self-reported)	3.15	3	1	2.2	0.00	1.0e+00	LRP1 RAB5B U91328.21
Myopia	3.14	2	0	0.0	0.00	1.0e+00	LRP1 LRRC37A
Schizophrenia (2018)	3.13	1	1	2.2	0.00	1.0e+00	U91328.21
High blood pressure	3.11	4	1	2.2	0.53	4.7e-01	ANKRD13A FHL5 HECTD4 RAB5B
Illnesses of father: Heart disease	3.10	1	0	0.0	0.00	1.0e+00	PHACTR1
Asthma	3.07	3	1	2.2	0.00	1.0e+00	LRP1 RAB5B U91328.21
Schizophrenia vs Biploar Disorder	3.02	1	0	0.0	0.00	1.0e+00	RP11-669E14.6
Age at first live birth	2.97	2	0	0.0	0.00	1.0e+00	CRHR1-IT1 RAB5B
Heel bone mineral density (BMD) T-score, automated (left)	2.92	2	1	2.2	0.00	1.0e+00	MAPT PPP1R3B
Respiratory disease	2.91	2	2	4.4	0.00	1.0e+00	LRP1 RAB5B
Tense / 'highly strung'	2.88	2	0	0.0	0.00	1.0e+00	CRHR1-IT1 PPP1R3B
Hypertension (Self-reported)	2.84	4	1	2.2	0.58	4.2e-01	ANKRD13A FHL5 HECTD4 RAB5B
Heart disease (mother)	2.82	1	0	0.0	0.00	1.0e+00	HECTD4
Average weekly red wine intake	2.81	1	0	0.0	0.00	1.0e+00	MED19
Schizophrenia (2014)	2.76	4	0	0.0	-0.98	1.9e-02	CEP170 CRHR1-IT1 LRRC37A MAPT
Suffer from 'nerves'	2.71	2	0	0.0	0.00	1.0e+00	CRHR1-IT1 RP11-669E14.6
Heart attack	2.70	1	1	2.2	0.00	1.0e+00	PHACTR1
Heart attack/myocardial infarction (self-reported)	2.67	1	1	2.2	0.00	1.0e+00	PHACTR1
Heel bone mineral density (BMD) T-score, automated (right)	2.64	4	1	2.2	-0.83	1.7e-01	AFF1 MAPT PPP1R3B RP11-669E14.6
Blood White Count	2.62	7	2	4.4	0.36	3.8e-01	ARL17B CRHR1-IT1 ECM1 HECTD4 KANSL1 MAPT RP11-669E14.6
Intelligence (Savage-Jansen 2018)	2.57	4	1	2.2	-0.99	7.7e-04	CRHR1-IT1 MAPT RAB5B RP11-669E14.6
Vascular/heart problems diagnosed by doctor	2.56	4	0	0.0	-0.55	4.5e-01	ANKRD13A FHL5 HECTD4 MEF2D
High blood pressure (mother)	2.53	2	0	0.0	0.00	1.0e+00	PHACTR1 TMEM170A
Smoking status: Previous	2.45	2	0	0.0	0.00	1.0e+00	HECTD4 RAB5B
Allergy or Eczema	2.36	3	1	2.2	0.00	1.0e+00	LRP1 RAB5B TMEM170A
Birth weight of first child	2.34	3	1	2.2	0.00	1.0e+00	HECTD4 RAB5B TMEM170A
Qualifications: None of the above	2.31	1	1	2.2	0.00	1.0e+00	RAB5B
Allergy	2.31	2	1	2.2	0.00	1.0e+00	LRP1 RAB5B
Chronotype (morning person)	2.21	2	2	4.4	0.00	1.0e+00	ECM1 HECTD4
Age when periods started (menarche)	2.18	2	0	0.0	0.00	1.0e+00	CRHR1-IT1 RP11-669E14.6
Angina	2.17	1	0	0.0	0.00	1.0e+00	PHACTR1
Multivitamins +/- minerals	2.13	1	0	0.0	0.00	1.0e+00	LRP1
Angina (self-reported)	2.11	1	0	0.0	0.00	1.0e+00	PHACTR1
Bipolar Disorder or Schizophrenia	2.06	2	1	2.2	0.00	1.0e+00	CEP170 U91328.21
Trunk fat percentage	2.06	7	0	0.0	-0.63	9.2e-02	CEP170 CRHR1-IT1 KANSL1 LRRC37A MAPT MED19 RP11-669E14.6
Smoking Status	2.05	3	1	2.2	0.00	1.0e+00	CRHR1-IT1 LRRC37A RAB5B
Medication: Ventolin 100micrograms inhaler	2.05	1	0	0.0	0.00	1.0e+00	RAB5B
LDL Cholesterol	2.04	1	0	0.0	0.00	1.0e+00	HECTD4
Hayfever, allergic rhinitis or eczema	1.98	2	1	2.2	0.00	1.0e+00	LRP1 RAB5B
Comparative height size at age 10	1.84	7	4	8.9	-0.54	1.7e-01	ARL17B CRHR1-IT1 HECTD4 LRRC37A MAPT RP11-669E14.6 U91328.21
Impedance of leg (left)	1.82	6	3	6.7	-0.97	2.9e-04	CRHR1-IT1 KANSL1 LRRC37A MAPT RAB5B RP11-669E14.6
Triglycerides	1.80	1	1	2.2	0.00	1.0e+00	AFF1
Reaction Time	1.75	2	1	2.2	0.00	1.0e+00	HECTD4 RAB5B
Hayfever/allergic rhinitis (self-reported)	1.74	2	0	0.0	0.00	1.0e+00	LRP1 RAB5B
Pulse rate, automated reading	1.73	2	1	2.2	0.00	1.0e+00	MEF2D RAB5B
Age started oral contraceptive pill	1.73	1	0	0.0	0.00	1.0e+00	RAB5B
Back pain experienced in last month	1.70	1	0	0.0	0.00	1.0e+00	HECTD4
Supplements: Fish oil (including cod liver oil)	1.66	1	0	0.0	0.00	1.0e+00	LRP1
Seen doctor (GP) for nerves, anxiety, tension or depression	1.64	1	0	0.0	0.00	1.0e+00	U91328.21
Mineral and other dietary supplements	1.64	1	0	0.0	0.00	1.0e+00	LRP1
Overall health rating	1.63	1	1	2.2	0.00	1.0e+00	CEP170
BMI	1.62	5	1	2.2	0.13	8.4e-01	CEP170 FHL5 LRP1 MEF2D RAB5B
Impedance of leg (right)	1.62	5	1	2.2	-0.96	3.0e-03	CRHR1-IT1 KANSL1 MAPT RAB5B RP11-669E14.6
Medication: Atenolol	1.62	1	0	0.0	0.00	1.0e+00	HECTD4
Ever had prostate specific antigen (PSA) test	1.61	1	0	0.0	0.00	1.0e+00	U91328.21
Blood Platelet Count	1.60	8	5	11.1	0.71	3.3e-02	CRHR1-IT1 KANSL1 LRRC37A MAPT MED19 MEF2D RP11-669E14.6 TMEM170A
Cardiovascular Disease	1.57	4	1	2.2	0.54	4.6e-01	ANKRD13A FHL5 HECTD4 RAB5B
Trunk fat mass	1.56	3	0	0.0	0.00	1.0e+00	CEP170 HECTD4 MED19
Body fat percentage	1.56	3	0	0.0	0.00	1.0e+00	CEP170 LRP1 MED19
Comparative body size at age 10	1.51	1	0	0.0	0.00	1.0e+00	U91328.21
Mean time to correctly identify matches	1.51	1	1	2.2	0.00	1.0e+00	HECTD4
Body mass index (BMI)	1.49	4	1	2.2	0.54	4.6e-01	CEP170 HECTD4 PPP1R3B RAB5B
Irritable Bowel Disease (IBD)	1.45	1	0	0.0	0.00	1.0e+00	ECM1
Height	1.43	13	10	22.2	-0.54	4.5e-02	AFF1 ARL17B CRHR1-IT1 ECM1 HECTD4 KANSL1 LRP1 LRRC37A MAPT MEF2D RARRES1 RP11-669E14.6 TMEM170A
Leg fat percentage (right)	1.43	3	0	0.0	0.00	1.0e+00	FHL5 HECTD4 LRP1
Leg fat percentage (left)	1.42	2	0	0.0	0.00	1.0e+00	CEP170 LRP1
Waist circumference	1.41	2	0	0.0	0.00	1.0e+00	HECTD4 RAB5B
Leg fat mass (right)	1.40	3	0	0.0	0.00	1.0e+00	CEP170 HECTD4 RAB5B
Medication: Aspirin	1.40	1	0	0.0	0.00	1.0e+00	MEF2D
Leg fat mass (left)	1.38	3	0	0.0	0.00	1.0e+00	CEP170 HECTD4 RAB5B
Whole body fat mass	1.34	3	0	0.0	0.00	1.0e+00	CEP170 HECTD4 RAB5B
Arm fat mass (right)	1.28	4	1	2.2	0.98	1.7e-02	CEP170 HECTD4 MED19 RAB5B
Hip circumference	1.26	3	1	2.2	0.00	1.0e+00	CEP170 HECTD4 RAB5B
Medication: Aspirin	1.22	1	0	0.0	0.00	1.0e+00	MEF2D
Arm fat percentage (right)	1.21	1	0	0.0	0.00	1.0e+00	MED19
Arm fat mass (left)	1.21	3	1	2.2	0.00	1.0e+00	CEP170 HECTD4 RAB5B
Arm fat percentage (left)	1.20	1	0	0.0	0.00	1.0e+00	MED19
Standing height	1.17	10	3	6.7	-0.34	3.1e-01	ARL17B CRHR1-IT1 HECTD4 KANSL1 LRP1 LRRC37A MAPT PPP1R3B RP11-669E14.6 U91328.21
Arm predicted mass (left)	1.09	2	2	4.4	0.00	1.0e+00	HECTD4 RAB5B
Arm fat-free mass (left)	1.07	2	2	4.4	0.00	1.0e+00	HECTD4 RAB5B
Weight	1.06	3	2	4.4	0.00	1.0e+00	CEP170 HECTD4 RAB5B
Medication: Laxatives (e.g. Dulcolax, Senokot)	1.06	1	0	0.0	0.00	1.0e+00	ECM1
Trunk predicted mass	0.97	2	2	4.4	0.00	1.0e+00	HECTD4 RAB5B
HDL Cholesterol	0.96	1	0	0.0	0.00	1.0e+00	AFF1
Trunk fat-free mass	0.96	2	2	4.4	0.00	1.0e+00	HECTD4 RAB5B
Basal metabolic rate	0.93	2	2	4.4	0.00	1.0e+00	HECTD4 RAB5B
Arm predicted mass (right)	0.92	2	2	4.4	0.00	1.0e+00	HECTD4 RAB5B
Whole body water mass	0.91	2	2	4.4	0.00	1.0e+00	HECTD4 RAB5B
Whole body fat-free mass	0.88	2	2	4.4	0.00	1.0e+00	HECTD4 RAB5B
Arm fat-free mass (right)	0.86	2	2	4.4	0.00	1.0e+00	HECTD4 RAB5B
Leg fat-free mass (left)	0.81	2	1	2.2	0.00	1.0e+00	HECTD4 RAB5B
Leg predicted mass (left)	0.81	2	1	2.2	0.00	1.0e+00	HECTD4 RAB5B
Leg fat-free mass (right)	0.76	2	1	2.2	0.00	1.0e+00	HECTD4 RAB5B
Leg predicted mass (right)	0.76	2	1	2.2	0.00	1.0e+00	HECTD4 RAB5B
Tanning	0.49	1	0	0.0	0.00	1.0e+00	ECM1
Hair Pigment	0.30	7	0	0.0	-0.62	9.9e-02	CRHR1-IT1 HECTD4 KANSL1 LRP1 MAPT PPP1R3B RP11-669E14.6

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Hippocampus	6	1.145	2.3
GTEx	Uterus	6	1.058	2.3
GTEx	Artery Coronary	10	0.845	2.2
GTEx	Cells EBV-transformed lymphocytes	9	0.632	2.1
GTEx	Small Intestine Terminal Ileum	4	0.868	2.1
GTEx	Artery Tibial	19	0.505	2.0
GTEx	Brain Frontal Cortex BA9	5	0.541	2.0
GTEx	Breast Mammary Tissue (Male)	7	0.587	2.0
GTEx	Ovary	6	0.661	2.0
GTEx	Vagina	5	0.787	2.0
GTEx	Adrenal Gland	7	0.480	1.9
GTEx	Artery Aorta	13	0.437	1.9
GTEx	Brain Cerebellar Hemisphere	8	0.537	1.9
GTEx	Brain Cortex	6	0.580	1.9
GTEx	Brain Hypothalamus	4	0.678	1.9
GTEx	Brain Nucleus accumbens basal ganglia	6	0.694	1.9
GTEx	Brain Putamen basal ganglia	5	0.801	1.9
GTEx	Colon Sigmoid	7	0.479	1.9
GTEx	Colon Transverse	9	0.436	1.9
GTEx	Esophagus Gastroesophageal Junction	8	0.554	1.9
GTEx	Pancreas	9	0.551	1.9
GTEx	Prostate	6	0.719	1.9
GTEx	Skin Not Sun Exposed Suprapubic	11	0.447	1.9
GTEx	Spleen	5	0.354	1.9
GTEx	Stomach	7	0.481	1.9
GTEx	Adipose Subcutaneous	11	0.315	1.8
GTEx	Adipose Visceral Omentum	9	0.442	1.8
GTEx	Brain Caudate basal ganglia	5	0.543	1.8
GTEx	Brain Cerebellum	6	0.303	1.8
GTEx	Breast Mammary Tissue	8	0.405	1.8
GTEx	Breast Mammary Tissue (Female)	9	0.547	1.8
GTEx	Cells Transformed fibroblasts	14	0.333	1.8
GTEx	Esophagus Mucosa	14	0.422	1.8
GTEx	Esophagus Muscularis	13	0.402	1.8
GTEx	Heart Atrial Appendage	7	0.443	1.8
GTEx	Liver	4	0.558	1.8
GTEx	Lung	9	0.313	1.8
GTEx	Muscle Skeletal	10	0.346	1.8
GTEx	Nerve Tibial	12	0.278	1.8
GTEx	Pituitary	5	0.448	1.8
GTEx	Skin Sun Exposed Lower leg	10	0.275	1.8
GTEx	Testis	11	0.349	1.8
GTEx	Thyroid	12	0.300	1.8
The Cancer Genome Atlas	Esophageal Carcinoma	3	0.438	1.8
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.281	1.8
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.394	1.8
GTEx	Heart Left Ventricle	8	0.523	1.7
GTEx	Whole Blood	7	0.351	1.7
NTR	Blood	7	0.291	1.7
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.273	1.7
The Cancer Genome Atlas	Lung Adenocarcinoma	5	0.170	1.7
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	4	0.301	1.7
METSIM	Adipose	5	0.108	1.6
CommonMind	Brain Pre-frontal Cortex	8	0.149	1.6
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	3	0.181	1.6
The Cancer Genome Atlas	Breast Invasive Carcinoma	4	0.091	1.6
The Cancer Genome Atlas	Glioblastoma Multiforme	4	0.391	1.6
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	4	0.147	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	5	0.122	1.6
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	3	0.146	1.6
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	5	0.200	1.6
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	4	0.251	1.6
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	3	0.181	1.6
The Cancer Genome Atlas	Prostate Adenocarcinoma	8	0.173	1.6
The Cancer Genome Atlas	Rectum Adenocarcinoma	3	0.434	1.6
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.6
The Cancer Genome Atlas	Stomach Adenocarcinoma	3	0.178	1.6
The Cancer Genome Atlas	Thyroid Carcinoma	7	0.136	1.6
ROSMAP	Brain Pre-frontal Cortex	2	0.046	1.5
YFS	Blood	4	0.087	1.5
The Cancer Genome Atlas	Colon Adenocarcinoma	1	0.048	1.5
The Cancer Genome Atlas	Brain Lower Grade Glioma	6	0.139	1.5
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	2	0.181	1.5
The Cancer Genome Atlas	Testicular Germ Cell Tumors	1	0.078	1.5